This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rukshin, V. Articles by Kaul, S. Search for Related Content PubMed PubMed Citation Articles by Rukshin, V. Articles by Kaul, S. Social Bookmarking                         What's this?

A Prospective, Nonrandomized, Open-Labeled Pilot Study Investigating the Use of Magnesium in Patients Undergoing Nonacute Percutaneous Coronary Intervention with Stent Implantation

Raul Santos, MD

Mitch Gheorghiu, MD

Prediman K. Shah, MD

Saibal Kar, MD

Sriram Padmanabhan, MD

Babak Azarbal, MD

Vivian T. Tsang, BS

Raj Makkar, MD

Bruce Samuels, MD

Norman Lepor, MD

Ivor Geft, MD

Steve Tabak, MD

Mehran Khorsandhi, MD

Neil Buchbinder, MD

Neil Eigler, MD

Bojan Cercek, MD

Keta Hodgson, RN

Sanjay Kaul, MD

Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, the Burns andAllen Research Institute, the Division of Cardiology, Department of Medicine, Cedars-Sinai Medical Center, and UCLA School of Medicine, Los Angeles, California

Background: Magnesium has recently been shown to inhibit acute stent thrombosis in animal models. This study tested the feasibility of magnesium administration in patients undergoing nonacute percutaneous coronary intervention with stent implantation.

Methods: Twenty-one patients undergoing nonemergent percutaneous coronary intervention were enrolled and received intravenous magnesium sulfate (2-g bolus over 20 minutes prepercutaneous coronary intervention, followed by 14 g over 12 hours infusion). Endpoints: safety outcomes-hypotension, bradycardia, bleeding complications and heart block within first 24 hours; angiographic outcomes-acute thrombotic occlusion and need for platelet glycoprotein Ilb/Illa inhibitor bailout; and clinical outcomes-death, myocardial infarction, recurrent ischemia, and need for urgent revascularization at 48 hours and 30 days.

Results: No significant effects on heart rate or blood pressure, major bleeding complication, or new electrocardiographic changes were observed. Angiographic thrombus was visualized in two cases, and coronary artery dissection in one case poststent deployment. None of these cases required the use of glycoprotein inhibitors for bailout. Death, myocardial infarction, recurrent ischemia, and need for urgent revascularization were not observed. The serum magnesium level increased from 2.1 ± 0.3 mg/dL at baseline to 3.5 ± 0.8 mg/dL at the end of the infusion (P < .0001). Platelet activation was significantly inhibited at the end of the magnesium sulfate infusion.

Conclusion: Intravenous magnesium sulfate has been demonstrated as a feasible and safe agent in patients undergoing nonacute percutaneous coronary intervention with stent implantation. A randomized clinical trial comparing magnesium with glycoprotein inhibitors during percutaneous coronary intervention is warranted.

Key Words: percutaneous coronary intervention • stent • antithrombotic effects • magnesium

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 8, No. 3, 193-200 (2003)
DOI: 10.1177/107424840300800304


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. M Collins, B. Chakraborty, S. A Murphy, and V. Strecher Comparison of a phased experimental approach and a single randomized clinical trial for developing multicomponent behavioral interventions Clinical Trials, February 1, 2009; 6(1): 5 - 15. [Abstract] [PDF]